Astrazeneca PLC (AZN): Price and Financial Metrics

AZN POWR Grades

• AZN scores best on the Growth dimension, with a Growth rank ahead of 84.95% of US stocks.
• The strongest trend for AZN is in Momentum, which has been heading down over the past 52 weeks.
• AZN ranks lowest in Momentum; there it ranks in the 18th percentile.

AZN Stock Summary

• Astrazeneca Plc's market capitalization of $160,641,280,000 is ahead of 98.56% of US-listed equities.
• AZN's current price/earnings ratio is 42.63, which is higher than 78.07% of US stocks with positive earnings.
• With a year-over-year growth in debt of 39.24%, Astrazeneca Plc's debt growth rate surpasses 84.04% of about US stocks.
• Stocks that are quantitatively similar to AZN, based on their financial statements, market capitalization, and price volatility, are SAP, NVS, ABBV, RTX, and SNY.
• Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to www.astrazeneca.com.

AZN Valuation Summary

• AZN's EV/EBIT ratio is 29.1; this is 0.68% lower than that of the median Healthcare stock.
• Over the past 243 months, AZN's price/sales ratio has gone up 2.7.
• Over the past 243 months, AZN's price/sales ratio has gone up 2.7.

Below are key valuation metrics over time for AZN.

AZN Growth Metrics

• Its year over year cash and equivalents growth rate is now at 123.73%.
• Its 2 year net income to common stockholders growth rate is now at -47.08%.
• The 4 year net income to common stockholders growth rate now stands at -51.22%.

AZN's revenue has moved up $7,186,000,000 over the prior 37 months.

The table below shows AZN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	29,528	6,446	3,768
2021-03-31	27,583	6,594	3,956
2020-12-31	26,617	4,799	3,144
2020-09-30	25,871	4,376	2,416
2020-06-30	25,699	3,657	2,045
2020-03-31	25,247	3,495	1,414

AZN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• AZN has a Quality Grade of B, ranking ahead of 78.06% of graded US stocks.
• AZN's asset turnover comes in at 0.438 -- ranking 106th of 681 Pharmaceutical Products stocks.
• CLVS, HSKA, and FLXN are the stocks whose asset turnover ratios are most correlated with AZN.

The table below shows AZN's key quality metrics over time.